CVS has announced that it will remove AbbVie’s rheumatoid arthritis drug adalimumab from some of its preferred drug reimbursement lists beginning in April 2024, according to an article published in Reuters. The pharmacy plans to instead recommend adalimumab biosimilars for coverage or reimbursement across all of its formularies. The CVS subsidiary Cordavis will also partner with AbbVie to develop a cobranded version of the drug that will be identical in formulation to AbbVie’s adalimumab—which it expects will become available to patients in the second quarter of 2024. The company explained that the move was intended to offer patients with rheumatoid arthritis a wider selection of drugs at a lower cost.